Editas Medicine and Beam Therapeutics rally on rumored deal
CRISPR/Cas9 gene editor Editas Medicine (NASDAQ:EDIT) and modified CRISPR gene editor Beam Therapeutics (NASDAQ:BEAM) are up 21% and 35%, respectively, premarket on chatter that a deal is imminent.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.